SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Akanda Corp. is a cannabis cultivation, manufacturing, and distribution company, which engages in the provision of premium quality and ethically sourced medical cannabis products to patients. The company cultivates and processes natural cannabis at facilities in the Kingdom of Lesotho, Africa and intend to supply medicinal-grade cannabis biomass, cannabis flower, and cannabis concentrates to wholesalers. It also imports and sells medical cannabis-based products. The company was founded on July 16, 2021 and is headquartered in New Romney, the United Kingdom.

Akanda Corp

Akanda Corp is experiencing a parabolic rally driven by its extremely low float and intense short-squeeze dynamics, with traders heavily focused on the stock's lack of available shares to borrow and astronomical borrow rates. While bulls are celebrating life-changing gains and pushing for triple-digit targets, many community members are expressing caution, citing the company's history of frequent reverse splits and ongoing dilution concerns as red flags.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is experiencing significant volatility as investors react to a massive earnings beat and strong forward guidance by engaging in profit-taking after a historic year-long rally. The community is sharply divided, with bulls pointing to the company's robust AI-driven data center growth and share buyback program as proof of long-term value, while bears are focused on potential overvaluation and the risk of a broader cyclical slowdown in the memory sector.

The White Alien has arrived. The countdown to domination starts now.

The White Alien

The White Alien is generating buzz through aggressive social media cross-promotion with various other memecoins, sparking intense community debate between optimistic traders betting on rapid price momentum and skeptics questioning the token's long-term legitimacy.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

Atlassian is trending following a double earnings beat that topped analyst expectations, signaling a potential sentiment shift for the broader SaaS sector. While some community members are skeptical of a lasting turnaround, many are actively discussing a rotation back into high-growth software as the company leans into AI integration to drive future revenue.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. Its products include CUE-400 series (autoimmune diseases), CUE-500 series (targeted cell depletion), and CUE-100 series (Oncology). The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

Cue Biopharma Inc

Cue Biopharma is currently experiencing extreme volatility and heavy volume as traders react to a recent preclinical milestone payment and an upcoming R&D presentation, while others express deep skepticism regarding the company's long-term performance and potential reverse split. The community is sharply divided, with bulls pointing to fundamental technology developments and Big Pharma partnerships, while bears highlight persistent dilution, management concerns, and a downward trend in share price.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is trending due to community anticipation surrounding the latest monthly Binance token burn, which investors believe will reduce supply and drive upward price momentum. Proponents are actively discussing long-term recovery goals and the potential for a supply shock, while skeptical traders continue to debate the project's viability following its historic market collapse.

NEOS ETF Trust - NEOS Nasdaq 100 High Income ETF

NEOS Nasdaq 100 High Income ETF

Investors are actively debating the merits of the NEOS Nasdaq 100 High Income ETF (QQQI), frequently comparing its tax-efficient return-of-capital structure and monthly distribution reliability against other income-focused holdings like JEPQ, SPYI, and SCHD. The community is focused on evaluating these ETFs as long-term income generators for retirement, with a particular emphasis on whether their covered call strategies provide better risk-adjusted returns and capital preservation compared to traditional growth indices.

iShares Bitcoin Trust ETF (The) - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin ETF

IBIT is currently trending as investors weigh mixed chart signals against robust institutional inflows, with the community actively debating whether to treat the asset as a bottoming opportunity or a risk-heavy proxy prone to volatility. Discussions are centered on critical technical thresholds, option market positioning, and the broader impact of institutional accumulation on Bitcoin's long-term price trajectory.

Alchemy Pay

Alchemy Pay is capturing significant community attention as investors debate its transition toward a Layer 1 blockchain and expansion of its fiat-to-crypto payment infrastructure. While some traders are bullish on new regulatory licensing and upcoming mainnet developments, others are actively debating concerns regarding token supply inflation and the project's long-term competitive moat against other payment solutions.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is trending as the stock undergoes a sharp re-rating alongside the broader software sector, with community discourse dominated by the 'SaaSpocalypse' narrative and conflicting views on whether AI serves as a long-term catalyst or an existential threat to its core business. Investors are closely monitoring the impact of aggressive share buybacks against shifting sentiment as the stock tests significant support levels amid heavy volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Harmony Biosciences (HRMY) Projected to Post Quarterly Earnings on Thursday

Harmony Biosciences (NASDAQ:HRMY) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at...

Q3 Earnings Estimate for HRMY Issued By HC Wainwright

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) - Equities researchers at HC Wainwright issued their Q3 2027 EPS estimates for shares of Harmony Biosciences in a research note issued...

Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026, before the open of the U.S. financial markets...

Ruffer LLP Purchases Shares of 40,993 Harmony Biosciences Holdings, Inc. $HRMY

Ruffer LLP purchased a new stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and...

Harmony Biosciences (NASDAQ:HRMY) Stock Price Up 12.6% - Should You Buy?

Harmony Biosciences (NASDAQ:HRMY) Shares Up 12.6% - Should You Buy...

<ul class="summary-bullets"><li>Mizuho stated in its note that AET Pharma is the sole remaining generic challenger that has yet to settle with Harmony Biosciences.</li><li>The firm believes Harmony’s Wakix franchise should be viewed as protected and fully intact through 2030.</li><li>Mizuho also noted that Harmony's lawsuit is a "significant development" and a "major positive" for the company.</li></ul>Shares of Harmony Biosciences Holdings Inc. (HRMY) soared more than 18% in Tuesday’s midday trade after analysts at Mizuho announced that they have learned of a new patent lawsuit filed by the company.According to TheFly, Mizuho analysts stated that Harmony Biosciences has sued AET Pharma for allegedly infringing a patent covering an amorphous formulation of pitolisant.<a href="https://stocktwits.com/symbol/HRMY">Harmony Biosciences shares</a> were up over 14% in Tuesday’s midday trade. Retail sentiment on Stocktwits about the company trended in ‘bullish’ territory, with message volume at ‘high’ levels at the time of writing.<h2 class="st-heading-2">What Is The Lawsuit About?</h2>Mizuho stated in its note that AET Pharma is the sole remaining generic challenger that has yet to settle with Harmony Biosciences. The lawsuit covers pitolisant, which was initially developed by Bioprojet and subsequently licensed exclusively by Harmony for the development, manufacture, and commercialization of pitolisant in the U.S.The firm now believes the Harmony Wakix franchise should be considered protected and fully intact through 2030. It also noted that Harmony's lawsuit is a "significant development" and a "major positive" for the company.Mizuho contended that this lawsuit should also remove a major overhang on HRMY stock stemming from concerns that a generic version of pitolisant could be launched before 2030.The firm reiterated its ‘Outperform’ rating on Harmony, with a $50 price target, implying an upside of about 50% from current levels.Koyfin data shows that the average 12-month price target for Harmony is $42, implying an upside of about 27% from current levels. Of the 11 analysts covering the stock, six have either a ‘Strong Buy’ or a ‘Buy’ recommendation, four have a ‘Hold’ rating, and one has a ‘Strong Sell’ recommendation.<h2 class="st-heading-2">What Is Pitolisant Used For?</h2>Pitolisant, originally developed to treat excessive daytime sleepiness and cataplexy in narcolepsy patients, is also being evaluated by Harmony Biosciences for use in individuals with Prader-Willi syndrome.The company also has two pitolisant tablet formulations, namely Pitolisant GR and Pitolisant HD.Harmony is developing Pitolisant GR to enable treatment initiation within the therapeutic dose range. Pitolisant HD is a reformulated version designed to improve how the drug works in the body and to target additional symptoms, such as fatigue, in patients with narcolepsy.Harmony announced in February this year that the U.S. Food and Drug Administration (FDA) approved Wakix (pitolisant) for the treatment of cataplexy in pediatric narcolepsy.“With this approval, clinicians now have the option to prescribe WAKIX to treat excessive daytime sleepiness, cataplexy, or both, in patients 6 years and older with narcolepsy,” said Harmony Biosciences’ Chief Medical and Scientific Officer, Kumar Budur.<a href="https://stocktwits.com/symbol/HRMY">HRMY stock</a> is down 10% year-to-date, but up 18% over the past 12 months. The iShares Core S&amp;P Small-Cap ETF (IJR) is up 43% over the past 12 months, while the iShares Russell 2000 ETF (IWM) is up 51%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/velo-stock-soars-best-gains-4-months-what-is-fueling-rally/cZBI8d9RI6e">VELO Stock Soars 38%, Races Toward Best Single-Day Move In 4 Months — What Is Fueling The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a stock chart on black background. | Image source: Getty Images

HRMY Stock On Track For Best Intraday Gains In 18 Months — What Did Mizuho Analysts Say?

Mizuho analysts stated that they have learned that Harmony Biosciences has filed a lawsuit against AET Pharma for allegedly infringing a patent covering an amorphous formulation of pitolisant.

Equity

Legend Biotech (LEGN) Moves 18.4% Higher: Will This Strength Last?

Legend Biotech (LEGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Average Recommendation of "Hold" by Brokerages

Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Get Free Report) have been assigned an average rating of "Hold" from the twelve analysts that are covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, five have issued a...

Harmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present encore open-label extension data from the companys investigation of EPX-100 (clemizole hydrochloride) in the...

Harmony Biosciences Appoints Glenn Reicin As CFO

(RTTNews) - Pharmaceutical company Harmony Biosciences Holdings, Inc. (HRMY) announced Tuesday the appointment of Glenn Reicin as Chief Financial Officer, effective immediately. Harmony is also reiterating its 2026 net product revenue guidance of $1.0 to $1.04 billion...

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the provision of development and commercialization of therapies for the treatment of neurological disorders. Its product, WAKIX, is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded by Jeffrey S. Aronin on July 25, 2017 and is headquartered in Plymouth Meeting, PA.

HRMY
Harmony Biosciences Holdings Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest HRMY News

HRMYHarmony Biosciences Holdings Inc